source
- Genmab’s Rina-S ADC shows 9.5-month median PFS, touted as superior to AbbVie’s ElahereGenmab reported median progression‑free survival of 9.5 months for its FRα‑directed antibody‑drug conjugate Rina‑S in part C of the phase 1/2 Rainfol‑01 trial, which enrolled 109 patients with plat…
- Nobel-winning optogenetics opens path to experimental therapies for blindness and Alzheimer’sOptogenetics, a technique that uses light to control neurons, earned a 2026 Nobel Prize. Researchers say the method is transforming brain mapping from a simple roadmap to a detailed, three-dimensi…